Vivoryon Therapeutics NV (FRA:05Y) PS Ratio: (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:05Y Vivoryon Therapeutics NV FRA:05Y
38 GF Score
Price €1.17
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Vivoryon Therapeutics NV's share price is €1.17. Vivoryon Therapeutics NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00. Hence, Vivoryon Therapeutics NV's PS Ratio for today is .

The historical rank and industry rank for Vivoryon Therapeutics NV's PS Ratio or its related term are showing as below:

During the past 13 years, Vivoryon Therapeutics NV's highest PS Ratio was 35.50. The lowest was 12.97. And the median was 20.19.

FRA:05Y's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.3
* Ranked among companies with meaningful PS Ratio only.

Vivoryon Therapeutics NV's Revenue per Sharefor the six months ended in Dec. 2025 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00.

Back to Basics: PS Ratio


Vivoryon Therapeutics NV  (FRA:05Y) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Vivoryon Therapeutics NV PS Ratio Related Terms


Vivoryon Therapeutics NV PS Ratio Historical Data

* Premium members only.

The historical data trend for Vivoryon Therapeutics NV's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV PS Ratio Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.32 0.00 0.00 0.00 0.00

Vivoryon Therapeutics NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:05Y vs VRTX, REGN, ALNY: PS Ratio Comparison

For the Biotechnology subindustry, Vivoryon Therapeutics NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivoryon Therapeutics NV PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's PS Ratio distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's PS Ratio falls into.


FRA:05Y
38GF Score
Vivoryon Therapeutics NV FRA:05Y
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivoryon Therapeutics NV PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Vivoryon Therapeutics NV's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.17/0
=

Vivoryon Therapeutics NV's Share Price of today is €1.17.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vivoryon Therapeutics NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
38GF Score

Get the complete analysis for FRA:05Y

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.17
Price